Abuse of Buprenorphine in the United States

Risk Management & Health Policy, Purdue Pharma L.P., Stamford, CT 06901-3431, USA.
Journal of Addictive Diseases (Impact Factor: 1.46). 02/2007; 26(3):107-11. DOI: 10.1300/J069v26n03_12
Source: PubMed


This study examines trends in the reported abuse of two sublingual buprenorphine products, Subutex and Suboxone, in the United States. Quarterly counts of abuse cases were obtained from 18 regional poison control centers (PCCS) for 2003-2005. Seventy-seven abuse cases were reported, of which 7.8 percent involved Subutex and 92.2 percent involved Suboxone. The average quarterly ratio of abuse cases per 1,000 prescriptions dispensed was 0.08 (SD +/- 0.09) for Subutex, and 0.16 (SD +/- 0.08) for Suboxone. Findings suggest that these sublingual buprenorphine formulations have a low rate of abuse based on toxico-surveillance data.

Download full-text


Available from: Meredith Smith, Feb 03, 2015
31 Reads
    • "Furthermore, there is evidence suggesting that buprenorphine diversion is an increasing problem.[20] Although, where toxicological measures are recorded nationally diversion seems to be less of a problem—the average quarterly ratio of abuse cases per 1000 Subutex (the trade name for buprenorphine when used to treat opioid dependence) prescriptions dispensed in the USA was only 0.08.[21] "
    [Show abstract] [Hide abstract]
    ABSTRACT: Heroin dependence is a major health and social problem associated with increased morbidity and mortality that adversely affects social circumstances, productivity, and healthcare and law enforcement costs. In the UK and many other Western countries, both methadone and buprenorphine are recommended by the relevant agencies for detoxification from heroin and for opioid maintenance therapy. However, despite obvious benefits due to its unique pharmacotherapy (eg, greatly reduced risk of overdose), buprenorphine has largely failed to overtake methadone in managing opioid addiction. The experience from the developing world (based on data from India) is similar. In this article we compare the advantages and disadvantages of the use methadone and buprenorphine for the treatment of opioid addiction from both a developed and developing world perspective; and explore some of the reasons why buprenorphine has not fulfilled the expectations predicted by many in the addictions field.
    Journal of Neurosciences in Rural Practice 03/2012; 3(1):45-50. DOI:10.4103/0976-3147.91934
  • Source
    • "In the United States, buprenorphine is predominantly available in coformulated tablets with naloxone. Multiple studies confirm that buprenorphine diversion is occurring in the United States, although rates of diversion of buprenorphine have been reported to be similar to or lower than those of methadone and other opioid analgesics (Cicero and Inciardi, 2005; JBS International and Maxwell, 2006; Cicero et al., 2007; Smith et al., 2007). "
    [Show abstract] [Hide abstract]
    ABSTRACT: We examined the use, procurement, and motivations for the use of diverted buprenorphine/naloxone among injecting and noninjecting opioid users in an urban area. A survey was self-administered among 51 injecting opioid users and 49 noninjecting opioid users in Providence, RI. Participants were recruited from a fixed-site syringe exchange program and a community outreach site between August and November 2009. A majority (76%) of participants reported having obtained buprenorphine/naloxone illicitly, with 41% having done so in the previous month. More injection drug users (IDUs) than non-IDUs reported the use of diverted buprenorphine/naloxone (86% vs 65%, P = 0.01). The majority of participants who had used buprenorphine/naloxone reported doing so to treat opioid withdrawal symptoms (74%) or to stop using other opioids (66%) or because they could not afford drug treatment (64%). More IDUs than non-IDUs reported using diverted buprenorphine/naloxone for these reasons. Significantly more non-IDUs than IDUs reported ever using buprenorphine/naloxone to "get high" (69% vs 32%, P < 0.01). The majority of respondents, both IDUs and non-IDUs, were interested in receiving treatment for opioid dependence, with greater reported interest in buprenorphine/naloxone than in methadone. Common reasons given for not being currently enrolled in a buprenorphine/naloxone program included cost and unavailability of prescribing physicians. The use of diverted buprenorphine/naloxone was common in our sample. However, many opioid users, particularly IDUs, were using diverted buprenorphine/naloxone for reasons consistent with its therapeutic purpose, such as alleviating opioid withdrawal symptoms and reducing the use of other opioids. These findings highlight the need to explore the full impact of buprenorphine/naloxone diversion and improve the accessibility of buprenorphine/naloxone through licensed treatment providers.
    Journal of Addiction Medicine 09/2011; 5(3):175-80. DOI:10.1097/ADM.0b013e3182034e31 · 1.76 Impact Factor
  • Source
Show more